|

OriCAR-017 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • OriCell Therapeutics Co., Ltd.1

Indications

  • Immune System Diseases1
  • Immunoproliferative Disorders1
  • Hemorrhagic Disorders1
  • Blood Protein Disorders1
  • Paraproteinemias1

Atlanta, Georgia1 trial

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Northside Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.